Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab-Reference-Cited by-同舟云学术

Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab

Published:2021-02-27 Issue:4 Volume:41 Page:332-341
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Tan Chia Jie¹²^ORCID,Kumar Rajneesh³,Koomanan Narendran¹,Loo Wei Sheng²,Farid Mohamad⁴,Tao Miriam⁴,Somasundaram Nagavalli⁴,Poon Eileen⁴,Chan Jason Yongsheng⁴,Yang Valerie Shiwen⁴⁵,Chang Esther⁴,Lim Soon Thye⁴,Chow Wan Cheng³,Chan Alexandre²⁶^ORCID,Tang Tiffany⁴

Affiliation:

1. Department of Pharmacy National University of Singapore Singapore City Singapore

2. Department of Pharmacy National Cancer Centre Singapore Singapore City Singapore

3. Department of Gastroenterology and Hepatology Singapore General Hospital Singapore City Singapore

4. Division of Medical Oncology National Cancer Centre Singapore Singapore City Singapore

5. Institute of Molecular and Cell Biology A*STAR Singapore City Singapore

6. Department of Clinical Pharmacy Practice School of Pharmacy and Pharmaceutical Sciences University of California Irvine California USA

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2508

Reference25 articles.

1. Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis

2. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

3. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

4. American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy

5. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy;Journal of Medical Virology;2023-02

2. Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma;Scientific Reports;2022-05-05

3. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy;Frontiers in Immunology;2021-10-08